Loading quotes...
Forecast
The analysts' average price target is €16.24 (+9,452.94%). The median is €16.24 (+9,452.94%).
| Buy |
4 |
| Hold |
6 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -1.39m | 85.36% |
| EBITDA | -1.39m | 83.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.31m |
Number of shares | 19.34m |
52-week high/low | €84.99 - €0.10 |
| Dividends | No |
Beta | -2.41 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
| Name | Kala Pharmaceuticals |
| CEO | Avi Minkowitz |
| Employees | 6 |
